In line with these findings, we observed that DZNep treatment led to a reduction in pulmonary fibrosis biomarkers (e.g., COL4A1, MMP14, and SERPINE1) and upregulation of factors counteracting fibrotic processes (e.g., ELAFIN, SLPI, and ECM1; Fig 4D). Here, COL4A1 is linked to pulmonary fibrosis.